Immunovia successfully completes discovery phase of next-generation test development
LUND (SWEDEN) – Immunovia (Nasdaq Stockholm: IMMNOV), the diagnostics company focused on early detection of pancreatic cancer, today announced the successful completion of the discovery phase for the Company’s next-generation test.
The discovery study, which marks a key milestone in the development of Immunovia’s next-generation test to detect early-stage pancreatic cancer, successfully found more than a dozen proteins circulating in the blood that identified pancreatic ductal adenocarcinoma (PDAC) stage I and stage II patients. The study is the most comprehensive pancreatic proteomics study done to date and utilized the Olink platform to explore nearly 3,000 protein biomarkers. The new test is designed to work across all racial and ethnic groups without compromising accuracy, overcoming a key limitation of Immunovia’s first-generation test, IMMray PanCan-d.
“We are excited to announce significant progress in the development of our next-generation test to detect early-stage pancreatic cancer. In the past three months, we have significantly restructured and streamlined our operations, which is paying off with the rapid and cost-efficient development of our next-generation test,” Jeff Borcherding, Immunovia CEO.
“The discovery study was completed quickly thanks to Immunovia’s extensive repository of in-house blood samples from PDAC patients and controls. We now have identified multiple combinations of novel protein biomarkers that appear to outperform both CA19-9 and IMMray PanCan-d,” Borcherding added.
Immunovia and its development partner Proteomedix are in the process of developing high- quality assays to accurately measure the identified biomarkers. The next step will be to complete a study to select which biomarkers to include in the commercial test, optimize the test, and assess its accuracy. Later in 2024, Immunovia will confirm the analytical validity of the test and conduct a large clinical validation study.
Immunovia has selected the ELISA platform, a commercially available platform, for the next generation test, which will enable the company to scale testing more rapidly and at a lower cost compared to the prior proprietary IMMray platform.
For more information, please contact:
Jeff Borcherding
CEO
jeff.borcherding@immunovia.com
Karin Almqvist Liwendahl
CFO
karin.almqvist.liwendahl@immunovia.com
+46 70 911 56 08
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
USA is the world’s largest market for detection of pancreatic cancer. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.
Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com
###
Tags: